KG LEGAL \ INFO
BLOG

Live Reporting as Evidence: Broadcast Recordings, Newsroom Logs and Journalistic Privilege in Digital Media

Publication date: November 17, 2026

Legal status as of 12 November 2026

News media increasingly operate in real time: a television broadcast, an online stream and a social media post are produced in parallel, and every editorial decision leaves a trace in IT systems. For law enforcement, this creates new sources of evidence; for newsrooms, new risks. Taking as an example a prosecutor’s order requiring a licensed broadcaster to produce a broadcast recording and logs from its playout and graphics systems, we discuss the limits of these powers, the protection of journalistic privilege, the legal status of digital material and the rules of liability for live reporting.

More

Synthetic data generation: the technology and its legal framework in the EU and Poland

Publication date: November 16, 2026

Legal status as at 11 November 2026

Synthetic data, meaning text, images and tabular records produced by algorithms rather than collected from the real world, has moved from the research lab into everyday business use. It promises datasets that can be shared, tested and used to train AI without exposing real individuals. The law, however, does not accept that promise at face value. In 2026 the European Data Protection Board stated that synthetic data is not anonymous by default, the AI Act’s transparency duties for synthetic content began to apply, and Poland established its own AI supervisory authority. This article explains how synthetic data is generated and what legal conditions its generation and use must meet.

More

Ageing biomarkers as evidence of geroprotective efficacy

Publication date: November 10, 2026

Clinical research, diagnostic testing and commercialisation under Polish and EU law

Law as at 5 November 2026

Abstract

A change in an epigenetic clock may justify further investigation of a medicine. Its value as evidence of benefit depends on what the clock measures, the population in which it has been validated and whether treatment effects on the score predict effects on health. The same assay may be used to analyse archived samples, select participants for treatment or sell a test to consumers. Each use raises a different legal question. This article traces those questions from trial design through to commercial use, with particular attention to Polish law on medical experiments, performance studies, access to medical records and the use of data from non-commercial clinical trials.

Keywords  ageing biomarkers, geroprotectors, clinical trials, IVDR, biobanks, genetic data

More

Paying Interest on Bad Code: Why Technical Debt Has Become a Legal Problemh

Publication date: November 04, 2026

Technical debt, GDPR and NIS2 – how yesterday’s shortcuts turn into tomorrow’s liability

Why technical debt arises

Technical debt is a phenomenon that sooner or later affects almost every IT project. It consists in choosing a solution that is quicker to deliver but inferior in technical quality. A team usually “takes out” this loan under pressure from the business side, for which the key metric is time-to-market – the sooner the product reaches the market, the better.

In the short term this brings a quick win, but in the future the company has to start paying the “interest”. It shows up as ever higher system maintenance costs, a slowdown in the pace of work, and the mounting frustration of developers who, instead of developing the product, must keep fixing the same defects over and over. Although the term “technical debt” appears nowhere in legislation, concepts such as due diligence and the adequacy of technical measures in practice force companies to keep that debt from spiralling out of control.

More

Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective

Publication date: October 12, 2026

I. Introduction

The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.

More

UP